Published in Diabetes Care on November 01, 2006
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia (2010) 4.33
Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther (2012) 0.97
Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value. Core Evid (2007) 0.80
Pro's and con's of the early use of insulin in the management of type 2 diabetes: a clinical evaluation. Curr Opin Endocrinol Diabetes Obes (2009) 0.77
Long-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes. CADTH Technol Overv (2010) 0.76
Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes. PLoS One (2014) 0.75
Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis. Open Med (2008) 0.75
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care (2007) 6.24
Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care (2006) 4.72
Nephropathy in diabetes. Diabetes Care (2004) 4.08
Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes (2006) 3.67
Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care (2007) 3.55
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest (2014) 3.31
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY. Endocr Pract (2016) 3.01
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab (2002) 2.98
beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab (2004) 2.91
Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes (2004) 2.86
Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes (2008) 2.76
What is the best predictor of future type 2 diabetes? Diabetes Care (2007) 2.64
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes (2003) 2.63
Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab (2004) 2.59
Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology (2007) 2.50
Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology (2012) 2.49
Identification of individuals with insulin resistance using routine clinical measurements. Diabetes (2005) 2.46
Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med (2008) 2.39
Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension (2004) 2.33
Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study. Diabetes (2007) 2.26
Gastric bypass and banding equally improve insulin sensitivity and β cell function. J Clin Invest (2012) 2.19
Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int (2011) 2.14
Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab (2006) 2.09
Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab (2002) 2.08
Peripheral disruption of the Grb10 gene enhances insulin signaling and sensitivity in vivo. Mol Cell Biol (2007) 2.08
Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes (2003) 2.02
Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes (2007) 1.96
Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. Diabetes (2011) 1.96
Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol (2010) 1.92
Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J (2005) 1.88
Diabetic nephropathy. Diabetes Care (2003) 1.87
Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol (2007) 1.86
Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care (2008) 1.81
Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab (2002) 1.73
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients (2013) 1.73
Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab (2005) 1.73
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology (2009) 1.71
Meal and oral glucose tests for assessment of beta -cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab (2002) 1.71
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab (2007) 1.70
Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. J Biol Chem (2004) 1.69
Pathophysiology of prediabetes. Curr Diab Rep (2009) 1.67
Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab (2004) 1.67
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab (2008) 1.67
Quantification of liver glucose metabolism by positron emission tomography: validation study in pigs. Gastroenterology (2006) 1.66
Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev (2006) 1.66
Heme oxygenase-1 induction remodels adipose tissue and improves insulin sensitivity in obesity-induced diabetic rats. Hypertension (2009) 1.61
Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab (2004) 1.60
Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes (2005) 1.57
Reduced time points to calculate the composite index. Diabetes Care (2010) 1.56
Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol (2007) 1.55
Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes (2002) 1.51
The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J Lipid Res (2009) 1.48
Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci U S A (2009) 1.45
Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab (2006) 1.44
Reduced skeletal muscle inhibitor of kappaB beta content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training. Diabetes (2006) 1.41
Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab (2006) 1.41
Does reduced IGF-1R signaling in Igf1r+/- mice alter aging? PLoS One (2011) 1.39
Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type. Cardiovasc Diabetol (2009) 1.38
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes (2012) 1.38
The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab (2008) 1.37
Physiological and molecular determinants of insulin action in the baboon. Diabetes (2008) 1.34
Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab (2004) 1.31
Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus. Curr Diab Rep (2008) 1.31
Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral fat. Hypertension (2008) 1.27
Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care (2002) 1.26
Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract (2008) 1.25
Plasma glucose concentration and prediction of future risk of type 2 diabetes. Diabetes Care (2009) 1.25
Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab (2004) 1.24
Pathophysiology of prediabetes. Med Clin North Am (2011) 1.24
Whole body overexpression of PGC-1alpha has opposite effects on hepatic and muscle insulin sensitivity. Am J Physiol Endocrinol Metab (2009) 1.23
Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance. Am J Physiol Endocrinol Metab (2008) 1.23
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2012) 1.22
Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab (2007) 1.22
An accurate and robust method for unsupervised assessment of abdominal fat by MRI. J Magn Reson Imaging (2004) 1.20
LKB1-AMPK signaling in muscle from obese insulin-resistant Zucker rats and effects of training. Am J Physiol Endocrinol Metab (2005) 1.20
Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. J Clin Endocrinol Metab (2004) 1.16
beta-cell function in obesity: effects of weight loss. Diabetes (2004) 1.13
Accurate segmentation of subcutaneous and intermuscular adipose tissue from MR images of the thigh. J Magn Reson Imaging (2009) 1.12
The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care (2006) 1.11
PROactive: time for a critical appraisal. Eur Heart J (2008) 1.11
Insulin reduces plasma arginase activity in type 2 diabetic patients. Diabetes Care (2007) 1.10
Distinct β-cell defects in impaired fasting glucose and impaired glucose tolerance. Diabetes (2012) 1.10
Effect of acute hyperglycemia on insulin secretion in humans. Diabetes (2002) 1.10
Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism (2002) 1.10